1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. CDK
  4. CDK5 Inhibitors

CDK5 Inhibitors

CDK1

CDK2

CDK3

CDK4

CDK5

CDK6

CDK7

CDK8

CDK9

CDK11

CDK12

CDK13

CDK14

CDK16

CDK19

CDC

CLK

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform CDK5 together.

Please try each isoform separately.

CDK5 Specific Inhibitors
Product Name CDK5 CDK1 CDK2 CDK3 CDK4 CDK6 CDK7 CDK8 CDK9 CDK14 CDK16 CDK5 Selectivity Purity
Abemaciclib methanesulfonate
Cdk5/p25, IC50: 355 nM
CDK5/p35, IC50: 287 nM
CDK1/cyclinB1, IC50: 1627 nM
CDK2/cyclinE, IC50: 504 nM
 
Cdk4/cyclin D1, IC50: 2 nM
CDK6/cyclinD1, IC50: 10 nM
CDK7/Mat1/cyclinH1, IC50: 3910 nM
 
CDK9/cyclinT1, IC50: 57 nM
    Pan Inhibitor 99.95%
(R)​-​CR8 trihydrochloride
Cdk5/p25, IC50: 0.11 μM
CDK1/cyclinB1, IC50: 0.09 μM
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
     
CDK7/cyclin H, IC50: 1.1 μM
 
CDK9/Cyclin T, IC50: 0.18 μM
    Pan Inhibitor 99.02%
Dinaciclib
CDK5, IC50: 1 nM
CDK1, IC50: 3 nM
CDK2, IC50: 1 nM
         
CDK9, IC50: 4 nM
    Pan Inhibitor 99.73%
Abemaciclib
CDK5/p35, IC50: 287 nM
Cdk5/p25, IC50: 355 nM
CDK1/cyclinB1, IC50: 1627 nM
CDK2/cyclinE, IC50: 504 nM
 
Cdk4/cyclin D1, IC50: 2 nM
CDK6/cyclinD1, IC50: 10 nM
CDK7/Mat1/cyclinH1, IC50: 3910 nM
 
CDK9/cyclinT1, IC50: 57 nM
    Pan Inhibitor 99.69%
Seliciclib
CDK5/p35, IC50: 0.16 μM
cdc2/cyclin B, IC50: 0.65 μM
cdk2/cyclin A, IC50: 0.7 μM
Cdk2/cyclin E2, IC50: 0.7 μM
                Pan Inhibitor 99.94%
Samuraciclib hydrochloride
CDK5/p35NCK, IC50: 9.4 μM
CDK1/cyc A, IC50: 1.8 μM
cdk2/cyclin A, IC50: 578 nM
 
CDK4/Cyc D1, IC50: 49 μM
CDK6/cycD1, IC50: 34 μM
CDK7/cyclin H, IC50: 41 nM
 
CDK9/CycT1, IC50: 1.2 μM
    Pan Inhibitor 99.98%
AT7519
CDK5/p35, IC50: 13 nM
Cdk1/cyclin B, IC50: 210 nM
cdk2/cyclin A, IC50: 47 nM
 
Cdk4/cyclin D1, IC50: 100 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
 
CDK9/Cyclin T, IC50: 10 nM
    Pan Inhibitor 98.15%
AZD-5438
cdk5-p25, IC50: 14 nM
cdk1-cyclin B1, IC50: 16 nM
cdk2-cyclin E, IC50: 6 nM
cdk2-cyclin A, IC50: 45 nM
 
cdk4-cyclin D1, IC50: 449 nM
cdk6-cyclin D3, IC50: 21 nM
cdk7-cyclin H, IC50: 821 nM
 
cdk9-cyclin T, IC50: 20 nM
    Pan Inhibitor 99.37%
GSK 3 Inhibitor IX
CDK5/p35, IC50: 80 nM
Cdk1/cyclin B, IC50: 320 nM
cdk2/cyclin A, IC50: 300 nM
 
Cdk4/cyclin D1, IC50: 10 μM
            Pan Inhibitor 99.66%
PHA-767491 hydrochloride
CDK5, IC50: 460 nM
CDK1, IC50: 250 nM
CDK2, IC50: 240 nM
         
CDK9, IC50: 34 nM
    Pan Inhibitor 99.91%
BS-181
CDK5/p35NCK, IC50: 3 μM
CDK1/cycB, IC50: 8.1 μM
CDK2/Cyc E, IC50: 0.88 μM
 
CDK4/Cyc D1, IC50: 33 μM
CDK6/cycD1, IC50: 47 μM
CDK7/CycH/MAT1, IC50: 0.021 μM
 
CDK9/cycT, IC50: 4.2 μM
    Pan Inhibitor 99.62%
THZ2
CDK5, IC50: 134 nM
CDK1, IC50: 96.9 nM
CDK2, IC50: 222 nM
     
CDK7, IC50: 13.9 nM
CDK8, IC50: 6830 nM
CDK9, IC50: 194 nM
    Pan Inhibitor 99.03%
Atuveciclib
CDK5/p35(h), IC50: 1600 nM
CDK1/CycB(h), IC50: 1100 nM
CDK2/CycE(h), IC50: 1000 nM
CDK3/CycE(h), IC50: 890 nM
       
CDK9/CycT1, IC50: 13 nM
CDK9/CycT1(h), IC50: 6 nM
    Pan Inhibitor 99.20%
Purvalanol A
cdk5-p35, IC50: 75 nM
cdc2-cyclin B, IC50: 4 nM
cdk2-cyclin E, IC50: 35 nM
cdk2-cyclin A, IC50: 70 nM
 
cdk4-cyclin D1, IC50: 850 nM
            Pan Inhibitor 98.66%
R547
CDK5/p35, IC50: 0.1 nM
Cdk1/cyclin B, Ki: 2 nM
Cdk1/cyclin B, IC50: 0.2 nM
CDK2/cyclinE, Ki: 3 nM
cdk2/cyclin A, IC50: 0.1 nM
CDK2/cyclinE, IC50: 0.4 nM
CDK3/Cyclin E, IC50: 0.8 nM
CDK4/cyclin D, Ki: 1 nM
cdk6/cyclin D3, IC50: 4 nM
CDK7/cyclin H, IC50: 171 nM
        Pan Inhibitor 99.66%
PHA-793887
Cdk5/p25, IC50: 5 nM
Cdk1/cyclin B, IC50: 60 nM
cdk2/cyclin A, IC50: 8 nM
CDK2/cyclinE, IC50: 8 nM
 
Cdk4/cyclin D1, IC50: 62 nM
 
CDK7/cyclin H, IC50: 10 nM
 
CDK9/cyclinT1, IC50: 138 nM
    Pan Inhibitor 99.95%
AT7519 Hydrochloride
CDK5/p35, IC50: 13 nM
Cdk1/cyclin B, IC50: 210 nM
cdk2/cyclin A, IC50: 47 nM
 
Cdk4/cyclin D1, IC50: 100 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
 
CDK9/Cyclin T, IC50: 10 nM
    Pan Inhibitor 99.99%
MC180295
cdk5-p35, IC50: 159 nM
cdk5-p25, IC50: 186 nM
CDK1-Cyclin B, IC50: 138 nM
cdk2-cyclin A, IC50: 233 nM
cdk2-cyclin E, IC50: 367 nM
CDK3-Cyclin E, IC50: 399 nM
CDK4-Cyclin D, IC50: 112 nM
cdk6-cyclin D3, IC50: 712 nM
CDK7-CycH/MAT1, IC50: 555 nM
 
CDK9- Cyclin T1, IC50: 5 nM
    Pan Inhibitor 98.47%
Lerociclib dihydrochloride
CDK5/p35, IC50: 832 nM
Cdk5/p25, IC50: 1.2 μM
CDK1/cyclinB1, IC50: 2.4 μM
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
 
Cdk4/cyclin D1, IC50: 1 nM
cdk6/cyclin D3, IC50: 2 nM
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
 
CDK9/Cyclin T, IC50: 28 nM
    Pan Inhibitor 98.45%
Purvalanol B
CDK5/p35, IC50: 6 nM
cdc2/cyclin B, IC50: 6 nM
cyclin dependent kinase 1-cyclinB, IC50: 6 nM
cdk2/cyclin A, IC50: 6 nM
CDK2/cyclinE, IC50: 9 nM
 
Cdk4/cyclin D1, IC50: 10000 nM
            Pan Inhibitor >97.0%
JSH-150
Cdk5/p25, IC50: 4.64 μM
Cdk1/cyclin B, IC50: 1.34 μM
cdk2/cyclin A, IC50: 2.86 μM
     
CDK7/Cyclin H/MNAT1, IC50: 1.72 μM
 
CDK9/cyclinT1, IC50: 1 nM
CDK14/Cyclin Y, IC50: 1.68 μM
CDK16/Cyclin Y, IC50: 292 nM
Pan Inhibitor 98.36%
NG 52
Pho85p, IC50: 2 nM
cdc2-cyclin B, IC50: 0.34 μM
                  Pan Inhibitor 99.93%
(R)​-​CR8
Cdk5/p25, IC50: 0.11 μM
Cdk1/cyclin B, IC50: 0.09 μM
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
     
CDK7/cyclin H, IC50: 1.1 μM
 
CDK9/Cyclin T, IC50: 0.18 μM
    Pan Inhibitor >98.0%
NU6140
cdk5-p25, IC50: 15 μM
CDK1-Cyclin B, IC50: 6.6 μM
cdk2-cyclin A, IC50: 0.41 μM
 
CDK4-Cyclin D, IC50: 5.5 μM
 
cdk7-cyclin H, IC50: 3.9 μM
        Pan Inhibitor >99.0%
Alsterpaullone
CDK5/p35, IC50: 40 nM
Cdk1/cyclin B, IC50: 35 nM
cdk2/cyclin A, IC50: 15 nM
CDK2/Cyc E, IC50: 200 nM
                Pan Inhibitor 97.30%
5-Iodo-indirubin-3'-monoxime
Cdk5/p25, IC50: 20 nM
Cdk1/cyclin B, IC50: 25 nM
                  Pan Inhibitor 99.50%
PNU112455A hydrochloride
CDK5, Km: 3.2 μM
 
CDK2, Km: 3.6 μM
                Pan Inhibitor 99.62%
AT7519 trifluoroacetate
CDK5/p35, IC50: 13 nM
Cdk1/cyclin B, IC50: 210 nM
cdk2/cyclin A, IC50: 47 nM
 
Cdk4/cyclin D1, IC50: 100 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
 
CDK9/Cyclin T, IC50: 10 nM
    Pan Inhibitor 98.16%
PHA-767491
CDK5, IC50: 460 nM
CDK1, IC50: 250 nM
CDK2, IC50: 240 nM
         
CDK9, IC50: 34 nM
    Pan Inhibitor
BS-181 hydrochloride
CDK5/p35NCK, IC50: 3 μM
CDK1/cycB, IC50: 8.1 μM
CDK2/Cyc E, IC50: 0.88 μM
 
CDK4/Cyc D1, IC50: 33 μM
CDK6/cycD1, IC50: 47 μM
CDK7/CycH/MAT1, IC50: 0.021 μM
 
CDK9/cycT, IC50: 4.2 μM
    Pan Inhibitor
NVP-LCQ195
Cdk5/p25, IC50: 1 nM
CDK5/p35, IC50: 1 nM
Cdk1/cyclin B, IC50: 2 nM
cdk2/cyclin A, IC50: 2 nM
CDK2/cyclinE, IC50: 5 nM
CDK3/Cyclin E, IC50: 42 nM
 
cdk6/cyclin D3, IC50: 187 nM
CDK7/Cyclin H/MAT1, IC50: 3564 nM
 
CDK9/cyclinT1, IC50: 15 nM
    Pan Inhibitor 99.80%
Lerociclib
CDK5/p35, IC50: 0.832 μM
Cdk5/p25, IC50: 1.2 μM
CDK1/cyclinB1, IC50: 2.4 μM
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
 
Cdk4/cyclin D1, IC50: 1 nM
cdk6/cyclin D3, IC50: 2 nM
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
 
CDK9/Cyclin T, IC50: 28 nM
    Pan Inhibitor
BS-181 dihydrochloride
CDK5, IC50: 3000 nM
 
CDK2, IC50: 880 nM
     
CDK7, IC50: 21 nM
 
CDK9, IC50: 4200 nM
    Pan Inhibitor
Indirubin-3'-monoxime-5-sulphonic acid
CDK5, IC50: 7 nM
CDK1, IC50: 5 nM
                  Pan Inhibitor
Indirubin-5-sulfonate
CDK5/p35, IC50: 65 nM
Cdk1/cyclin B, IC50: 55 nM
cdk2/cyclin A, IC50: 35 nM
CDK2/cyclinE, IC50: 150 nM
 
Cdk4/cyclin D1, IC50: 300 nM
            Pan Inhibitor
CDK5 inhibitor 20-223
CDK5, IC50: 8.8 nM
 
CDK2, IC50: 6.0 nM
                Pan Inhibitor